Microbubble protein delivery for Parkinson’s by unknown
ORAL PRESENTATION Open Access
Microbubble protein delivery for Parkinson’s
James Keenan1*, Umar Iqbal2, Maria Moreno2, Jagdeep Sandhu2
From Current and Future Applications of Focused Ultrasound 2014. 4th International Symposium
Washington, D.C, USA. 12-16 October 2014
Background/introduction
Microbubbles (MBs) are small (1-5 μm diameter), perfluor-
carbon gas filled lipid microspheres used for contrast
enhancement during ultrasound imaging. MBs (Definity®,
others) are approved for contrast echocardiography and
widely used (6 M patient injections) as ultrasound contrast
agents with established pharmacokinetics and clearance
data. Recent research has shifted to the therapeutic poten-
tial of MBs and the NRC and Artenga Inc. developed a
novel strategy (Patent to be filed) to load biologics onto
MBs with high, consistent loading using a novel clinically
scalable methodology.
Investigators at Sunnybrook Research Institute have pio-
neered MR guided focused ultrasound (MRgFUS) plus MB
techniques to deliver a wide range of therapeutic agents
through the blood-brain-barrier (BBB) and developed a state
of the art MRgFUS system for animal models. MRgFUS can
precisely target the substantia nigra (SN) and striatum (ST)
for simultaneous targeting of multiple brain regions.
Neurotrophic factors (NTFs) are being developed in the
hope of halting or reversing the progression of neuronal
loss in chronic neurodegenerative diseases, however, their
clinical utility is limited by drug delivery issues. Recently
the University of Helsinki discovered a novel NTF, cere-
bral dopamine neurotrophic factor (CDNF), with a unique
structure and mode of action. CDNF has demonstrated
improved efficacy compared to GDNF in various preclini-
cal models of PD. Artenga, Inc., Sunnybrook Research
Institute, the National Research Council of Canada (NRC),
and the University of Helsinki plan is to use MR guided
focused ultrasound (MRgFUS) and neurotrophic drug-
loaded microbubbles (NTF-MBs) for targeted, noninva-
sive, blood brain barrier (BBB) drug delivery of CDNF.
Methods
Although CDNF neuroprotection and neurorestoration
data are promising, clinical development might be
hampered by its inability to cross the BBB and rely on deliv-
ery methods that are either highly invasive or non-targeted.
Hence, our focus on non-invasive targeted delivery of
CDNF into the SN and ST using CDNF-MBs coupled with
MRgFUS to open the BBB for the delivery of therapeutic
doses of CDNF. Artenga’s goal is to commercialize our
technology to treat multiple diseases with different com-
pounds and tumour-targeting agents. The Artenga-NRC
MB conjugation technology permits extremely high and
consistent drug loading per MB for a wide range of com-
pounds including antibodies, proteins, complex 3D folded
antibodies, antibody drug conjugates, and gene therapy.
The covalent bond results in reliable in vivo performance.
The technology can also be adopted for cancer treatments.
A novel therapeutic method of action was developed at
Sunnybrook Research Institute to damage tumour vascula-
ture using focused ultrasound and MBs. The technique has
shown synergy with chemotherapy to significantly increase
tumour reduction compared to the drug alone. Testing is
ongoing with tumour targeting MBs. Indications suitable
for treatment with drug loaded MBs and focused ultra-
sound include Parkinson’s disease, other CNS disorders,
and different types of cancer. For cancer applications a
tumour targeting, drug loaded MB will be used.
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